Inovio Pharmaceuticals(US:INO) TMX Newsfile·2026-02-16 14:02Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals, Inc. due to allegations of violations of federal securities laws related to misleading statements and inadequate disclosures regarding the company's product development and regulatory prospects [4][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Inovio to contact them to discuss their legal options, particularly for those who purchased securities between October 10, 2023, and December 26, 2025 [1]. - There is a deadline of April 7, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Inovio [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Allegations Against Inovio - The complaint alleges that Inovio and its executives made false and misleading statements regarding the manufacturing of the CELLECTRA device and the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [4]. - It is claimed that Inovio lacked sufficient information to justify the eligibility of INO-3107 for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [4]. - Following the FDA's announcement that it accepted Inovio's BLA for INO-3107 on a standard review timeline, Inovio's stock price fell by $0.56 per share, or 24.45%, closing at $1.73 per share on December 29, 2025 [5][6].